Related Experiment Videos
Indomethacin treatment for polyhydramnios and subsequent infantile nephrogenic diabetes insipidus
L G Smith1, B Kirshon, D B Cotton
1Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX 77030.
American Journal of Obstetrics and Gynecology
|July 1, 1990
Insights
Indomethacin effectively treated polyhydramnios and nephrogenic diabetes insipidus by reducing urine output. This medication managed both prenatal and postnatal excessive urination in a single patient case study.
Area of Science:
- Perinatology
- Nephrology
- Pharmacology
Background:
- Polyhydramnios, characterized by excessive amniotic fluid, poses risks to both mother and fetus.
- Nephrogenic diabetes insipidus (NDI) is a condition where kidneys do not respond to antidiuretic hormone, leading to excessive urination.
Observation:
- A patient diagnosed with polyhydramnios received treatment involving amniotic fluid decompression and indomethacin.
- Six months postpartum, the same patient was diagnosed with nephrogenic diabetes insipidus.
Findings:
- Indomethacin demonstrated efficacy in managing polyhydramnios.
- Indomethacin was also effective in treating nephrogenic diabetes insipidus in this patient.
- The mechanism of action involved reducing urine output, thereby controlling polyuria.
Implications:
- Indomethacin presents a potential therapeutic option for both polyhydramnios and NDI.
- This case highlights the dual role of indomethacin in managing conditions associated with excessive fluid loss or accumulation.
- Further research may explore indomethacin's broader applications in managing polyuric states.
Abstract:
A case of polyhydramnios was effectively treated with amniotic fluid decompression and indomethacin. Six months later nephrogenic diabetes insipidus was diagnosed and indomethacin was again effectively used. By reducing urine output, indomethacin controlled both in utero and extrauterine polyuria in this patient.